Skip to main content
PLOS One logoLink to PLOS One
. 2020 Aug 24;15(8):e0237917. doi: 10.1371/journal.pone.0237917

Simultaneous evaluation of metabolomic and inflammatory biomarkers in children with different body mass index (BMI) and waist-to-height ratio (WHtR)

Erika Chavira-Suárez 1,#, Cecilia Rosel-Pech 1,2,#, Ernestina Polo-Oteyza 3, Mónica Ancira-Moreno 1,4, Isabel Ibarra-González 5, Marcela Vela-Amieva 6, Noemi Meraz-Cruz 1, Carlos Aguilar-Salinas 7, Felipe Vadillo-Ortega 1,8,*
Editor: Nayanatara Arun Kumar9
PMCID: PMC7446833  PMID: 32834003

Abstract

Metabolic disturbances and systemic pro-inflammatory changes have been reported in children with obesity. However, it is unclear the time-sequence of metabolic or inflammatory modifications during children obesity evolution. Our study aimed to quantify simultaneously metabolomic and inflammatory biomarkers in serum from children with different levels of adiposity. For this purpose, a cross-sectional study was used to perform targeted metabolomics and inflammatory cytokines measurements. Serum samples from children between six to ten years old were analyzed using either body mass index (BMI) or waist-to-height ratio (WHtR) classifications. One hundred and sixty-eight school-aged children were included. BMI classification in children with overweight or obesity showed altered concentrations of glucose and amino acids (glycine and tyrosine). Children classified by WHtR exhibited imbalances in amino acids (glycine, valine, and tyrosine) and lipids (triacyl glycerides and low-density lipoprotein) compared to control group. No differences in systemic inflammation biomarkers or in the prevalence of other results were found in these children. Abnormal arterial blood pressure was found in 32% of children with increased adiposity. In conclusion, obesity in school-aged children is characterized by significant metabolic modifications that are not accompanied by major disturbances in circulating concentrations of inflammatory biomarkers.

Introduction

An increasing and alarming prevalence of overweight (OV) and obesity (OB) in children has been documented worldwide. Chile, USA, New Zealand and Mexico are among the countries with the highest reported prevalence [13]. Determinants of pediatric obesity are a complex interplay between high energy intake and a low energy expenditure with genetic and epigenetic factors, neuroendocrine modulation, intrauterine exposures, sleeping habits, physical activity, and socioeconomic level [4]. Abnormal adiposity starting in childhood introduces a higher risk for early development of metabolic syndrome, type 2 diabetes and cardiovascular diseases, among many other complications [5,6]. Current understanding of the deleterious effects of increased adiposity points to lipotoxicity as the initial mechanism of disease.

Lipotoxicity is a term reflecting the damaging effects of systemic chronic increased availability of free fatty acids (FFA) that induces reactive oxygen species (ROS) production, impaired mitochondrial function and metabolic adjustments in several tissues, accompanying systemic insulin resistance [7] and release of pro-inflammatory cytokines [8]. Metabolic adjustments include accumulation of FFA in non-adipose tissues such as skeletal muscle, heart, pancreas, liver and kidney, and the wide use of lipids as a major source for catabolism, associated to incomplete fatty acids β-oxidation [9] and suppression of the insulin intracellular pathways that mediate glucose uptake in tissues [10]. Also, FFA accumulation can increase the formation of abnormal autophagosomes in beta cells, inducing endoplasmic reticulum stress which it could be a factor in the progression from obesity to diabetes [11].

Increased availability of circulating FFA can exceed the adipose tissue storage capacity and directly stimulate toll-like receptor 4 (TLR4) in blood mononuclear cells, inducing the secretion of pro-inflammatory cytokines [8]. In addition, secretions of mediators such as retinol-binding protein 4 (RBP-4), leptin, adipsin, vaspin, resistin, c-reactive protein (CRP), adiponectin, and omentin-1 promote imbalance in glucose and lipid metabolism, breaking down the insulin-sensitizing mechanisms, signal transduction, and triggering insulin resistance, ROS overproduction, energy uncoupling in mitochondria, cellular apoptosis and necrosis and reduced nitric oxide (NO) production [12,13].

Changes in metabolic substrates availability by physiological and pathophysiological conditions could be measured by diverse biochemical and molecular technical approaches. Currently, metabolomics is becoming a powerful tool for identifying metabolic signatures associated with healthy or unhealthy phenotypes. For example, the metabolomic analysis in blood samples from children with obesity and type 2 diabetes enables to detect metabolites changes that have pathophysiological relevance in clinical practice for hyperinsulinism and insulin resistance treatment [14]. The screening for metabolic profiling in children with different obesogenic background may facilitate individual or personalized pediatric interventions [15]. However, it still unclear if alterations in metabolic substrates are a consequence of inflammatory factors that responded to obesity condition or that metabolic imbalances promote pro-inflammatory response in children.

Few efforts have been directed to evaluate the specific contribution, timing and interactions of the metabolic and inflammatory mechanisms of damage in obesity, especially in children in which the consequences of these disturbances can initiate an early-life process of accumulating damaging effects on health. In this work we compare the presence of specific metabolomic disturbances and levels of blood pro-inflammatory mediators in a cross-sectional study of school-aged children stratified both by body mass index (BMI) and waist-to-height ratio (WHtR).

Methods

Subjects

One hundred and sixty-eight Mexican children between six to ten years old were invited to participate through a signed consent form by them and their parents. They were randomly selected from a cohort of 1,312 school-aged children attending 2012–2013’s cycle of public elementary school at the City of Toluca, State of Mexico, Mexico. They were classified by their BMI and WHtR for further metabolomic and immunological analyses. Children were excluded if previous diagnosis of type 1 and type 2 diabetes, dyslipidemia, hypertension or inflammatory diseases was presented. Sample size was calculated according to a previously published study in school-aged Mexican children for finding differences among mean values of serum cytokine concentrations between BMI groups [5].

Institutional Review Board of the Faculty of Medicine, National Autonomous University of Mexico (UNAM) granted authorization for this study (Register number: 2013–89) and, it has been conducted according to the principles expressed in the Declaration of Helsinki.

Anthropometric measurements

Height was measured with a stadiometer 217 model (Seca, Germany). Weight was obtained with a flat scale 876 model (Seca, Germany), and circumference of waist was measured with a measuring tape (Seca, Germany). Anthropometric measurements were assessed by standardized personnel, using Lohman techniques [16]. Arterial blood pressure, pulse and respiration rate were measured at rest. Blood pressure was obtained according to American Heart Association [17]. The BMI was calculated and BMI Z-scored according with World Health Organization (WHO) reference values [18]. The WHtR was calculated as the waist circumference (cm) divided by the height (cm). LMS tables for calculating WHtR in Z-scores and centiles based on National Health and Nutrition Examination Survey (NHANES) were applied to make comparisons [19]. Systolic (SBP) and diastolic (DBP) blood pressures (mmHg) percentiles for gender, age, and height were calculated following Eunice Kennedy Shriver National Institute (NICHD) recommendations.[20] Children with OV and OB were classified by BMI, using Z-score > 2.0 to ≤ 3.0 and > 3.0, respectively.[18] Cardiovascular risk group (CVR) in children was defined by WHtR at 65th percentile in girls and 77th percentile in boys [19].

Metabolomics

Venous blood samples were obtained under fasting conditions, and serum separated no later than fifteen minutes after venipuncture. Glucose (Gluc), triacylglycerols (TAG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were measured using a clinical chemistry analyzer (ISE SRL, Miura 200). Eleven L-amino acids including arginine (Arg), citruline (Cit), glycine (Gly), alanine (Ala), leucine (Leu), L-methionine (Met), L-phenylalanine (Phe), tyrosine (Tyr), Valine (Val), Ornithine (Orn), Proline (Pro), and twelve acylcarnitines including carnitine (C0), acetylcarnitine (C2), propionylcarnitine (C3), isobutyril-L-carnitine (C4), isovalerylcarnitine (C5), hexanoylcarnitine (C6), octanoylcarnitine (C8), decanoylcarnitine (C10), dodecanoylcarnitine (C12), tetradecanoylcarnitine (C14), L-palmitoylcarnitine (C16), and sterearoylcarnitine (C18), were measured by tandem mass spectrometry (Micromass Quattro micro API, Perkin Elmer) using the NeoLinx 4.1 software (Perkin Elmer). For each subject serum insulin (Ins) level was measured by ultrasensitive immunoassay method in a Beckman Coulter Access 2 system (Beckman Coulter Ireland, Inc.). From the Gluc and Ins determinations, HOMA-IR was calculated as follows: fasting blood Gluc (mmol/L) × fasting Ins (microIU/mL)/22.5.

Cytokine measurements

Fourteen cytokines including interleukins IL-1α, IL-1β, IL-2, IL-6, IL-10, IL-17, IL-1RA, IL-12p40, sIL-2RA, interferon gamma-induced protein 10 (IP10), tumor necrosis factor-α (TNFα), vascular endothelial growth factor (VEGF), macrophage inflammatory proteins (MIP1α), and MIP1β were measured in serum using Milliplex Multiplex Assays (Millipore, Burlington, MA, USA). Media fluorescence intensity, calculated from duplicates from each sample, was analyzed using the Luminex-100 software system version 1.7 (Luminex). Observations under lower limit of detection (LOD) for each cytokine were transformed for the analysis using LOD/2 square root method [21].

Statistical analysis

Numerical data are reported as the mean ± SD and its corresponding proportion by each group of BMI and WHtR classifications. Comparisons between group means were computed using 2-way ANOVA with post Fisher’s LSD test, Kruskal Wallis with Dunnett’s multiple comparison test, and U Mann Whitney where appropriate. Metabolites and cytokines were plotted by partial least squares-discriminant analysis (PLS-DA) and compared by multiple logistic regressions using the covariables of gender and age to distinguish main contributors in each group. Analyses were conducted using SPSS version 19 and MetaboAnalyst 3.0. Statistical significance was set at p ≤ 0.05.

Results

Among the 168 children included in this study, the mean age was 8.8 ± 1.3 years and approximately half of them were girls (46%; n = 78) and the other half boys (54%; n = 90). According to BMI classification, 77 (45%) of children corresponded to normal weight (NW), 45 (27%) to OV, and 46 (28%) to OB. Significant increments of DBP and SBP were found in children with OV and OB (Table 1).

Table 1. Characteristics of 168 schoolchildren classified by BMI.

Anthropometric values Normal weight Overweight Obesity
Girls Boys Both Girls Boys Both Girls Boys Both
N (%) N (%) N (%)
36 (21) 41 (24) 77 (45) 26 (16) 19 (11) 45 (27) 16 (10) 30 (18) 46 (28)
Mean ± SD Mean ± SD Mean ± SD
Weight (kg) 26 ± 5 24 ± 4 25 ± 5 37 ± 7b 33 ± 6a 35 ± 7a,b 44 ± 8c 42 ± 9c 43 ± 9c
Height (cm) 130 ± 9 127 ± 9 128 ± 9 136 ± 10b 130 ± 10a 133 ±10a,b 136 ± 8b 135 ± 10a,b 135 ± 9a,b
BMI (kg/m2) 15 ± 1 15 ± 1 15 ± 1 20 ± 2a 19 ± 1a 19 ± 2a 24 ± 2b 23 ± 2.5b 23 ± 2b
SBP (mmHg) 103 ± 15a 104 ± 11a 103 ± 13a 106 ± 1a,b 111 ± 9b 108 ±12b 107 ± 9a,b 109 ± 14a,b 109 ±13b
DBP (mmHg) 63 ± 11a 59 ± 11a 61 ± 11a 64 ± 13a,b 66 ± 11b 65 ± 12a,b 66 ± 10a,b 65 ± 11b 65 ± 10b

Descriptive results are expressed as the means ± SD, indicating the number of subjects (N) and the corresponding percentage (%). Two-way ANOVA post Fisher’s LSD test was used; statistical difference (p<0.05) between genders of the same group or between groups is shown with different letters. BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure

Children classified by WHtR showed that 84 (50%) of them belonged to the normal group (NG), and the other 84 (50%) belonged to the cardiovascular risk group (CVR). SBP and DBP values were significantly higher in children classified as CVR than NG (Table 2).

Table 2. Characteristics of 168 schoolchildren classified by WHtR.

Anthropometric values Normal Cardiovascular Risk
Girls (≤ 65th) Boys (≤ 77th) Both Girls (> 65th) Boys (> 77th) Both
N (%) N (%)
35 (21) 49 (29) 84 (50) 43 (26) 41 (24) 84 (50)
Mean ± SD Mean ± SD
Weight (kg) 27 ± 7 25 ± 5 26 ± 6 39 ± 9a 40 ± 10a 39 ± 9a
Height (cm) 131 ± 10a 128 ± 8a 130 ± 9a 135 ± 9a,b 133 ±11b 134 ± 10b
Waist (cm) 56 ± 5 56 ± 5 56 ± 5 75 ± 8a 76 ± 9a 75 ± 8a
WHtR/age 0.43 ± 0.03 0.43 ± 0.03 0.43 ± 0.03 0.55 ± 0.04a 0.57 ± 0.05b 0.56 ± 0.04a,b
SBP (mmHg) 101±14 105 ±11 103 ± 12 108 ± 13a 110 ± 12a 109 ±13a
DBP (mmHg) 62 ± 11a,b 60 ± 12a 61 ± 12a,b 66 ± 11b,c 65 ± 10c 65 ±11c

Descriptive results are expressed as the means ± SD, indicating the number of subjects (N) and the corresponding percentage (%). Two-way ANOVA post Fisher’s LSD test was used; statistical difference (p<0.05) between genders of the same group or between groups is shown by different letters. WHtR: waist to height ratio, SBP: Systolic blood pressure, DBP: diastolic blood pressure.

Further analysis of blood pressure values was processed using WHtR percentile ranks according to National Institutes of Health (NIH) and National Heart, Lung, and Blood Institute (NHLBI)[20]. This kind of analysis allowed us to identify children with different levels of hypertension risk: normal (<90th), prehypertension (≥90th <95th), hypertension state 1 (≥95th <99th), and hypertension state 2 (≥99th). Significative difference in prevalence of abnormal SBP was found in children classified as CVR (OR: 2.776, 95% IC: 1.14–6.76; p = 0.011) (Table 3).

Table 3. Classification by WHtR and blood pressure.

Classification Systolic Blood Pressure (mm Hg)
Normal Cardiovascular Risk
Girls Boys Both Girls Boys Both
Mean ± SD (N) Mean ± SD (N)
Normal (< 90th) 99 ±12 (32) 102 ± 8 (44) 101 ±10 (76) 103 ±9 (35) 105 ±10 (30) 104 ± 10 (65)
Prehypertension (≥ 90th < 95th) 120 (2) 119 (2) 119 ± 2 (4) 119 ± 1 (3) 118 ± 2 (4) 118 ± 2 (7)
Hypertension state I (≥ 95th < 99th) (0) (0) (0) 124 (2) 122 ± 2 (5) 123 ± 2 (7)
Hypertension state II (≥ 99th) 129 (1) 133 ± 10 (3) 132 ± 8 (4) 137 ± 2 (3) 138 (2) 137 ± 5 (5)
Diastolic Blood Pressure (mm Hg)
Normal (< 90th) 59 ± 7 (30) 57 ± 7 (45) 58 ± 7 (75) 62 ± 9 (36) 63 ± 9 (36) 63 ± 9 (72)
Prehypertension (≥ 90th < 95th) 79 ± 2 (3) 77 (1) 79 ± 2 (4) 80 (2) 79 (2) 79 ± 2 (4)
Hypertension state I (≥ 95th < 99th) 85 (1) (0) 85 (1) 83 ± 1 (4) 81 (2) 82 ± 2 (6)
Hypertension state II (≥ 99th) 89 (1) 95 ± 11 (3) 94 ± 6 (4) 88 (1) 83 (1) 86 ± 4 (2)

WHtR percentile ranks classification in children according to NHLBI Health Information Center of the National Institutes of Health [20].

In order to clarify if school-aged children with obesity-associated risks could has metabolic substrates altered, we measure metabolites involved in glucose, amino acids, and lipids metabolisms. Our findings showed that metabolomic profiles overlapped between groups either classified by BMI or WHtR (Fig 1).

Fig 1. Metabolites profile in serum from schoolchildren classified by BMI and WHtR.

Fig 1

(A—C) BMI classification; (D—F) WHtR classification. PLS-DA plots and loadings plots showing the maximum covariance between metabolites concentrations and the largest effect by children adiposity group.

In bivariate analysis, the values of Gluc, TAG, TC, LDL-c, C0, C14, C16, C3, C5, Gly, Val, and Tyr showed differences between NW and OB; while the values of Ins, HOMA-IR, C0, and C6 showed exclusively differences between NW and OV. The differences observed between NW and OB were pretty similar to those of NG and CVR, but in WHtR classification acylcarnitines C0, C6, C5 and the amino acid Gly expressed no differences between both groups; instead of it, HDL-c value was lower in CVR than NG (S1 Table). Despite this, after multiple logistic regression analysis only the Gluc, Gly, Phe, and Orn were different in children with OV/OB, as well as LDL-c, Gly, Val, and Orn were different in CVR; age and gender were not associated (Table 4).

Table 4. Multivariable model for prediction of metabolic alterations in schoolchildren.

BMI classification WHtR classification
Variable β S. E. χ2 Prob> χ2 β S. E. χ2 Prob> χ2
Intercept 11.5 4.7 6.00 0.014* 8.99 4.8 3.45 0.063
Gender 0.146 0.26 0.32 0.571 0.019 0.25 0.01 0.940
Age 0.080 0.20 0.17 0.682 -0.127 0.20 0.40 0.529
Gluc -0.105 0.05 4.93 0.026* -0.059 0.04 1.77 0.183
Ins -2.06 1.9 1.13 0.287 -1.52 1.9 0.64 0.425
HOMA-IR 7.67 8.2 0.88 0.347 5.81 8.0 0.52 0.470
TAG -0.003 0.01 0.19 0.663 -0.010 0.01 1.49 0.223
TC -0.002 0.02 0.02 0.902 0.014 0.02 0.60 0.439
LDL-c -0.028 0.02 1.55 0.213 -0.050 0.02 4.17 0.041*
HDL-c 0.036 0.03 2.01 0.156 0.034 0.03 1.52 0.218
C0 -0.001 0.11 0.00 0.989 -0.000 0.11 0.00 0.997
C2 -0.115 0.73 0.03 0.874 0.235 0.79 0.09 0.764
C4 13.5 13 1.03 0.310 15.3 13 1.33 0.249
C6 81.9 43 3.68 0.055 86.3 45 3.73 0.054
C8 8.71 14 0.41 0.523 17.1 13 1.64 0.200
C10 -11.1 19 0.33 0.567 -27.6 19 2.12 0.145
C12 0.386 41 0.00 0.993 44 41 1.12 0.290
C14 -91.9 110 0.70 0.404 -221 122 3.25 0.072
C16 12.3 33 0.14 0.706 18.9 33 0.32 0.571
C18 90.4 67 1.82 0.178 66.0 68 0.93 0.334
C3 12.3 13 0.87 0.350 5.1 13 0.16 0.685
C5 -61.3 32 3.64 0.0565 -19.0 32 0.36 0.549
Gly 0.033 0.01 9.75 0.009* 0.037 0.01 11.49 0.001*
Ala -0.005 0.01 0.22 0.642 0.007 0.01 0.31 0.575
Met 0.282 0.18 2.59 0.108 -0.077 0.17 0.22 0.642
Leu -0.038 0.05 0.67 0.413 0.048 0.05 1.12 0.289
Val -0.052 0.05 1.31 0.252 -0.107 0.05 5.44 0.020*
Phe 0.180 0.07 5.97 0.015* 0.054 0.07 0.58 0.447
Tyr -0.095 0.05 3.51 0.061 -0.076 0.05 2.72 0.099
Arg -0.078 0.05 2.73 0.099 -0.065 0.04 2.15 0.143
Cit 0.018 0.11 0.03 0.872 0.139 0.11 1.73 0.189
Orn -0.066 0.03 3.87 0.049* -0.074 0.03 5.42 0.020*
Pro -0.027 0.01 3.64 0.057 -0.016 0.01 1.64 0.201

Data with statistical difference is shown (bold*) obtained by ordinal logistic regression fit for BMI or WHtR. β: beta coefficient, S. E.: standard error, χ2: chi square, Glucose: Gluc, Ins: insulin, HOMA-IR: homeostasis model assessment insulin resistance, TAG: triglycerides, TC: total cholesterol, LDL-c: low-density lipoprotein cholesterol, HDL-c: high density lipoprotein cholesterol, C0: carnitine, C2: acetyl carnitine, C4: isobutyril carnitine, C6: hexanoyl carnitine, C8: octanoyl carnitine, C10: decanoyl carnitine, C12: dodecanoyl carnitine, C14: tetradecanoyl carnitine, C16: palmitoyl carnitine, C18: octadecanoylarnitine (stearoylcarnitine), C3: propionyl carnitine, C5: isovaleryl carnitine, Gly: glycine, Ala: alanine, Met: methyonine, Leu: leucine, Val: Valine, Phe: phenylalanine, Tyr: tyrosine, Arg: arginine, Cit: citrulline, Orn: ornitine, Pro: proline.

Finally, different cytokines were measured to determine if subclinical immunological response could be installed on school-aged children with total or central obesity. Levels of inflammatory cytokines showed no major differences between groups in both classifications (Fig 2).

Fig 2. Cytokines serum profile in schoolchildren classified by BMI or WHtR.

Fig 2

(A- B) BMI classification; (C-D) WHtR classification. PLS-DA plots show the maximum covariance between cytokines concentrations in children groups.

When we analyzed by bivariate analysis only MIP-1β was higher in CVR than NG (Table 5); but after multiple adjustments this difference disappeared.

Table 5. Cytokines concentration in serum by BMI and WHtR.

Cytokines BMI classification WHtR classification
NW OV OB NG CVR
Mean ± SD CI 95% Mean ± SD CI 95% Mean ± SD CI 95% Mean ± SD CI 95% Mean ± SD CI 95%
IL-1α 12 ± 21 7–16 13 ± 25 6–21 7 ± 9 5–10 11 ± 20 7–16 11 ± 19 7–15
IL-1β 2 ± 4 1–3 2 ± 2 1–2 1 ± 1 1–2 2 ± 4 1–3 1 ± 2 1–2
IL-6 5 ± 11 3–8 6 ± 13 2–9 3 ± 6 1–5 5 ± 11 3–7 4 ± 10 2–7
TNF α 7 ± 6 6–8 7 ± 3 6–8 7 ± 3 6–8 7 ± 5 5–8 7 ± 3 6–8
IL-17 3 ± 4 2–4 3 ± 2 2–3 3 ± 2 2–3 3 ± 4 2–4 3 ± 2 2–3
IL-1RA 18 ± 43 8–27 10 ± 15 5–14 5 ± 6 4–7 18 ± 41 9–27 7 ± 10 5–9
IL-10 3 ± 9 1–5 2 ± 5 1–4 2 ± 5 1–3 3 ± 8 1–5 2 ± 5 1–3
IL-12p40 9 ± 17 5–13 7 ± 9 4–10 5 ± 5 3–6 10 ± 17 6–14 5 ± 5 4–7
IL-2 3 ± 6 2–4 3 ± 3 2–4 2 ± 2 1–2 3 ± 6 2–4 2 ± 2 1–2
sIL-2RA 32 ± 66 17–47 19 ± 36 8–29 34 ± 62 15–52 33 ± 64 19–47 25 ± 52 14–36
VEGF 105±123 78–133 91 ± 138 50–133 100 ± 113 67–134 97 ±118 71–123 103±129 75–131
MIP-1 α 6 ± 5 5–7 7 ± 5 5–8 7 ± 5 5–8 6 ± 56 5–8 7 ± 4 6–8
MIP-1 β 50 ± 19 46–54 54 ± 19 49–60 56 ± 23 49–63 51 ± 21 46–55 55 ± 20* 51–60
IP-10 342±186 300–385 375±192 317–433 383 ± 258 307–459 343±181 304–383 380 ± 233 330–431

Kruskal Wallis with Dunnett’s multiple comparison tests were used to evaluate the parameters classified by BMI and, the U Mann Whitney test were used to evaluate parameters classified by WHtR. Single significant difference is signaled in bold* (p < 0.05).

Discussion

Rationale of this study was to simultaneously compare circulating metabolomic and inflammatory biomarkers in a cross-sectional study in healthy school-aged children classified by ranks of either BMI or WHtR. Our results support that metabolic disturbances precede changes in the inflammatory biomarkers in children with increased adiposity. It is well established that increased adiposity impacts metabolic homeostasis [22], and some of the involved lipid metabolites induce inflammatory response in the adipose tissue and other organs as obesity evolves. The specific contribution of these alterations in the natural history of obesity comorbidities is still not well identified.

In this study, we analyzed and compared metabolomic and inflammatory biomarkers in children stratified by BMI as a proxy of total body adiposity or WHtR as a proxy of upper body fat distribution around the abdomen. We decided to compare results using both classifications in order to address actual controversy about the accuracy of these anthropometric measures to predict metabolic health status [2326]. In our study we did not find significative differences using either BMI or WHtR for identification of children with either metabolic or inflammatory biomarkers disturbances.

Children with higher adiposity, either by BMI, showed increased glycemia in association to disturbances in lipid and amino acid metabolism, some of these results have been reported previously as a metabolic signature in obese children and adolescents [2730].

Lipid metabolism in children with increased adiposity is characterized by higher concentrations of circulating triglycerides, L-palmitoylcarnitine, and free carnitine, revealing increased availability of fatty acids for oxidation. No evidence of beta-oxidation disfunction was present in these children since no accumulation of circulating short or medium-chain acylcarnitines species was found, making sense that fatty acids oxidation is a major source of energy [31,32] and consequently they are displacing the use of glucose by tissues, manifested as higher glycemia values [33].

Amino acid metabolism showed also significative changes in children with higher adiposity; glycine decreased, and valine, phenylalanine, and ornithine increased. These metabolic features have been identified previously [27,29]. Reduced circulating concentration of glycine may be explained by funneling glycine to gluconeogenesis induced by higher concentrations of fatty acids, displacing the incorporation of pyruvate to Krebs cycle [34], which may contribute to increased concentration of blood glucose. No clear explanation exists for high concentration of branched-chain amino acids (BCAA) such as valine that was found increased in children with obesity, confirming previous reports [3539].

In comparison with metabolic disturbances, we did not find major differences in circulating inflammatory cytokines associated to increased adiposity in children classified either by BMI or WHtR. These findings contrast to a current report from Mărginean and cols where they noted an low-grade inflammatory status related to elevated counts of leukocytes, lymphocytes, and platelets in children with overweight and obesity [40]. However, they used a bivariate statistical analysis and no correction by age or sex of children was attempted. It is possible that younger children, as in our study, do not show the same cellular response. Inflammation is a complex tissular response that is frequently misinterpreted in obesity studies and further effort to homogenize terms such as "low-grade inflammation" must be accomplished in the literature [41]. Also, they did not find changes on glycemia levels indicating that adiposity in children may respond differentially according to lifestyles and genetic background. A cohort design is required to evaluate time course of inflammatory cytokine release to systemic circulation which have been proposed as independent cardiometabolic disease risk factors [4244].

MIP-1β was the only significative inflammatory biomarker increased in children with CVR classification. MIP-1β is a chemokine which concentration has been correlated with waist circumference in young adults [45]. MIP-1β production is induced by palmitate in adipose tissue suggesting that this could be part of the mechanisms linking metabolism and inflammation [46].

Prevalence of alterations in blood pressure in children are still poorly studied and the role of these alterations in cardiovascular pathologies during later phases of life is still not known. It is possible that many of these early metabolic and functional differences in children may have a developmental programing origin during pregnancy and early childhood.

Our study has some limitations such as a relatively small sample size and the lack of information about lifestyles outside of the school, as well as dietary and exercise habits. Although we considered in the study the age and gender as changing factors of circulating metabolic mediators, further longitudinal studies in children cohorts must be done to clarify the trajectories of metabolic substrates and adipose tissue accumulation correlated with their lifestyles. Genetic factors must be also considered in metabolic trajectories analyses during childhood.

Conclusion

Our findings suggest that school-aged children classified with abnormal adiposity show metabolic disturbances characterized by differential concentrations of circulating lipids and amino acids, that are not accompanied by systemic inflammatory response.

Supporting information

S1 Table. Metabolic profile in schoolchildren classified by BMI or WHtR.

Kruskal Wallis with Dunnett’s multiple comparison test were used to evaluate the parameters classified by BMI and, the U Mann Whitney test were used to evaluate parameters classified by WHtR. Significant differences (p < 0.05) between groups in both types of classification are shown with different letters. Gluc: Glucose, Ins: insulin, HOMA-IR: homeostasis model assessment insulin resistance, TG: triglycerides, TC: total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, C0: carnitine, C2: acetyl carnitine, C4: isobutyril carnitine, C6: hexanoyl carnitine, C8: octanoyl carnitine, C10: decanoyl carnitine, C12: dodecanoyl carnitine, C14: tetradecanoyl carnitine, C16: palmitoyl carnitine, C18: octadecanoylarnitine (stearoylcarnitine), C3: propionyl carnitine, C5: isovaleryl carnitine, Gly: glycine, Ala: alanine, Met: methyonine, Leu: leucine, Val: Valine, Phe: phenylalanine, Tyr: tyrosine, Arg: arginine, Cit: citrulline, Orn: ornitine, Pro: proline.

(DOCX)

Acknowledgments

We thank to all participants in this project including: Nohemí Morán Díaz, Yunuén Pruneda Padilla, Marcial López Cervantes, Mercedes Gutiérrez Mares, Rocío Urbina Arronte, Samantha Escudero Gontes, Roberto Enrique Estrada Barragán, Bárbara Noemí Pantaleón Torres, Irma Cristina Carbajal Castillo, Andrea Siles Miranda, Cynthia Denise Camacho Robles, Erick Álvarez Álvarez, Inti Pérez Casillas, Fernanda Martínez.

Data Availability

All relevant data are within the manuscript.

Funding Statement

Field work of this study was supported from Nestlé, S.A de C.V. under agreement 33059-2283-25-X-12 with Universidad Nacional Autónoma de México. I would like to state that Ernestina Polo-Oteyza, M.Sc. contributed as an author to this paper. She has a commercial affiliation as Director of Fondo Nestlé para la Nutrición in the Fundación Mexicana para la Salud. The funder provided support in the form of salaries for author EPO, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the ‘author contributions’ section.

References

  • 1.Organisation for Economic Cooperation and Development. Health at a Glance 2017: OECD Indicators. Paris, FR: OECD Publishing; 2017. [Google Scholar]
  • 2.Flores-Huerta S, Acosta-Cázeres B, Gutiérrez-Trujillo G. Prevalencia de peso bajo, sobrepeso, obesidad general y obesidad central. Rev Med Inst Mex Seguro Soc. 2006;44: 55–62. [PubMed] [Google Scholar]
  • 3.Vadillo-Ortega F, Rivera-Dommarco J, González de Cosio T, Garibay-Nieto N, García-Aranda J. Obesidad infantil In: Rivera-Dommarco JA, Hernández-Ávila M, Aguilar-Salinas CA, Vadillo-Ortega F, Murayama-Rendón C, editors. Obesidad en México: Recomendaciones para una política de Estado. Mexico City: UNAM-Dirección General de Publicaciones y Fomento Editorial; 2013. [Google Scholar]
  • 4.Koyuncuoglu Güngör N. Overweight and Obesity in Children and Adolescents. J Clin Res Pediatr Endocrinol. 2014;6: 129–143. 10.4274/Jcrpe.1471 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Perichart-Perera O, Balas-Nakash M, Schiffman-Selechnik E, Barbato-Dosal A, Vadillo-Ortega F. Obesity Increases Metabolic Syndrome Risk Factors in School-Aged Children from an Urban School in Mexico City. J Am Diet Assoc. 2007;107: 81–91. 10.1016/j.jada.2006.10.011 [DOI] [PubMed] [Google Scholar]
  • 6.Goodarzi MO. Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. Lancet Diabetes Endocrinol. 2018;6: 223–236. 10.1016/S2213-8587(17)30200-0 [DOI] [PubMed] [Google Scholar]
  • 7.Boden G. Free fatty acids (FFA), a link between obesity and insulin resistance. Front Biosci. 1998;3: 169–175. Available: http://www.ncbi.nlm.nih.gov/pubmed/9450985 [DOI] [PubMed] [Google Scholar]
  • 8.Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116: 1793–1801. 10.1172/JCI29069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Unger RH, Zhou YT. Lipotoxicity of β-cells in obesity and in other causes of fatty acid spillover. Diabetes. 2001;50: 1–4. 10.2337/diabetes.50.2007.S118 [DOI] [PubMed] [Google Scholar]
  • 10.Burgeiro A, Cerqueira MG, Varela-Rodríguez BM, Nunes S, Neto P, Pereira FC, et al. Glucose and Lipid Dysmetabolism in a Rat Model of Prediabetes Induced by a High-Sucrose Diet. Nutrients. 2017;9: 1–17. 10.3390/nu9060638 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Quan W, Jung HS, Lee MS. Role of autophagy in the progression from obesity to diabetes and in the control of energy balance. Arch Pharm Res. 2013;36: 223–229. 10.1007/s12272-013-0024-7 [DOI] [PubMed] [Google Scholar]
  • 12.Engin AB, Engin A. Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology. Ankara, Turkey: Springer Nature; 2017. 10.1007/978-3-319-48382-5_5 [DOI] [PubMed] [Google Scholar]
  • 13.Yang G, Li L, Fang C, Zhang L, Li Q, Tang Y, et al. Effects of free fatty acids on plasma resistin and insulin resistance in awake rats. Metabolism. 2005;54: 1142–1146. 10.1016/j.metabol.2005.03.020 [DOI] [PubMed] [Google Scholar]
  • 14.Martos-Moreno G, Mastrangelo A, Barrios V, Garciá A, Chowen JA, Rupérez FJ, et al. Metabolomics allows the discrimination of the pathophysiological relevance of hyperinsulinism in obese prepubertal children. Int J Obes. 2017;41: 1473–1480. 10.1038/ijo.2017.137 [DOI] [PubMed] [Google Scholar]
  • 15.Hellmuth C, Kirchberg FF, Brandt S, Moß A, Walter V, Rothenbacher D, et al. An individual participant data meta-analysis on metabolomics profiles for obesity and insulin resistance in European children. Sci Rep. 2019;9: 1–13. 10.1038/s41598-018-37186-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lohman T, Roche AF, Martorell R. Anthropometric standardization reference manual: Abridged edition. Champaign, IL: Human Kinetics Books; 1988. [Google Scholar]
  • 17.Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Cou. Circulation. 2005;111: 697–716. 10.1161/01.CIR.0000154900.76284.F6 [DOI] [PubMed] [Google Scholar]
  • 18.World Health Organization. AnthroPlus for Personal Computers. Manual: Software for assessing growth of the world ‘ s children. Geneva. 2007; 1–45. http://www.who.int/growthref/tools/en/
  • 19.Sharma AK, Metzger DL, Daymont C, Hadjiyannakis S, Rodd CJ. LMS tables for waist-circumference and waist-height ratio Z-scores in children aged 5–19 y in NHANES III: Association with cardio-metabolic risks. Pediatr Res. 2015;78: 723–729. 10.1038/pr.2015.160 [DOI] [PubMed] [Google Scholar]
  • 20.National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics. 2004;114: 555–576. Available: http://pediatrics.aappublications.org/content/114/Supplement_2/555.long [PubMed] [Google Scholar]
  • 21.Hornung R, Reed L. Estimation of average concentration in the presence of non-dectable valued. App Occup Environ Hyg. 1990. pp. 546–551. [Google Scholar]
  • 22.Khovidhunkit W, Kim M-S, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host. J Lipid Res. 2004;45: 1169–1196. 10.1194/jlr.R300019-JLR200 [DOI] [PubMed] [Google Scholar]
  • 23.Wohlfahrt-Veje C, Tinggaard J, Winther K, Mouritsen A, Hagen CP, Mieritz MG, et al. Body fat throughout childhood in 2647 healthy Danish children: Agreement of BMI, waist circumference, skinfolds with dual X-ray absorptiometry. Eur J Clin Nutr. 2014;68: 664–670. 10.1038/ejcn.2013.282 [DOI] [PubMed] [Google Scholar]
  • 24.Pietrobelli A, Faith MS, Allison DB, Gallagher D, Chiumello G, Heymsfield SB. Body mass index as a measure of adiposity among children and adolescents: A validation study. J Pediatr. 1998;132: 204–10. 10.1016/s0022-3476(98)70433-0 [DOI] [PubMed] [Google Scholar]
  • 25.Lindsay RS, Hanson RL, Roumain J, Ravussin E, Knowler WC, Tataranni PA. Body Mass Index as a Measure of Adiposity in Children and Adolescents: Relationship to Adiposity by Dual Energy X-Ray Absorptiometry and to Cardiovascular Risk Factors. J Clin Endocrinol Metab. 2001;86: 4061–4067. 10.1210/jcem.86.9.7760 [DOI] [PubMed] [Google Scholar]
  • 26.Ramírez-Vélez R, Correa-Bautista JE, Martínez-Torres J, González-Ruíz K, González-Jiménez E, Schmidt-Riovalle J, et al. Performance of two bioelectrical impedance analyses in the diagnosis of overweight and obesity in children and adolescents: The FUPRECOL study. Nutrients. 2016;8: 1–13. 10.3390/nu8100575 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Goffredo M, Santoro N, Tricò D, Giannini C, D’Adamo E, Zhao H, et al. A branched-chain amino acid-related metabolic signature characterizes obese adolescents with non-alcoholic fatty liver disease. Nutrients. 2017;9: 1–12. 10.3390/nu9070642 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gong CD, Wu QL, Chen Z, Zhang D, Zhao ZY, Peng YM. Glycolipid metabolic status of overweight/obese adolescents aged 9- to 15-year-old and the BMI-SDS/BMI cut-off value of predicting dyslipidemiain boys, Shanghai, China: A cross-sectional study. Lipids Heal Dis. 2013;12: 1 10.1186/1476-511X-12-129 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Perng W, Gillman MW, Fleisch AF, Michalek RD, Watkins SM, Isgnaitis E, et al. Metabolomic profiles and childhood obesity. Obes (Silver Spring). 2015;22: 2570–2578. 10.1002/oby.20901.Metabolomic [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Newbern D, Gumus Balikcioglu P, Balikcioglu M, Bain J, Muehlbauer M, Stevens R, et al. Sex Differences in Biomarkers Associated With Insulin Resistance in Obese Adolescents: Metabolomic Profiling and Principal Components Analysis. J Clin Endocrinol Metab. 2014;99: 4730–4739. 10.1210/jc.2014-2080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Cox RA, García-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. Boston, MA: Butterworths; 1990. pp. 153–160. https://www.ncbi.nlm.nih.gov/books/NBK351/ [Google Scholar]
  • 32.Vaz FM, Wanders RJ. Carnitine biosynthesis in mammals. Biochem J. 2002;361: 417–429. 10.1042/0264-6021:3610417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Hue L, Taegtmeyer H, Randle P, Garland P, Hales N. The Randle cycle revisited. Am J Physiol Endocrinol Metab. 2009;297: 578–591. 10.1152/ajpendo.00093.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Yan-Do R, MacDonald PE. Impaired “glycine”-mia in type 2 diabetes and potential mechanisms contributing to glucose homeostasis. Endocrinology. 2017;158: 1064–1073. 10.1210/en.2017-00148 [DOI] [PubMed] [Google Scholar]
  • 35.Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FGS, et al. Increased Levels of Plasma Acylcarnitines in Obesity and Type 2 Diabetes and Identification of a Marker of Glucolipotoxicity. Obes (Silver Spring). 2010;18: 1695–1700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Van Hinsbergh VW, Veerkamp JH, Engelen PJM, Ghijsen WJ. Effect of l-carnitine on the oxidation of leucine and valine by rat skeletal muscle. Biochem Med. 1978;20: 115–124. 10.1016/0006-2944(78)90056-x [DOI] [PubMed] [Google Scholar]
  • 37.Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012;15: 606–614. 10.1016/j.cmet.2012.01.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Wongkittichote P, Ah Mew N, Chapman KA. Propionyl-CoA carboxylase–A review. Mol Genet Metab. 2017;122: 145–152. 10.1016/j.ymgme.2017.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Krahenbuhl S, Brass EP. Inhibition of hepatic propionyl-CoA synthetase activity by organic acids. Reversal of propionate inhibition of pyruvate metabolism. Biochem Pharmacol. 1991;41: 1015–1023. 10.1016/0006-2952(91)90209-n [DOI] [PubMed] [Google Scholar]
  • 40.Mărginean CO, Meliţ LE, Ghiga DV, Mărginean MO. Early Inflammatory Status Related to Pediatric Obesity. Front Pediatr. 2019;7: 1–7. 10.3389/fped.2019.00001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Razavi A, Bagheri N, Azadegan-Dehkordi F, Shirzad M, Rahimian G, Rafieian-Kopaei M, et al. Comparative Immune Response in Children and Adults with H. pylori Infection. J Immunol Res. 2015;2015 10.1155/2015/315957 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.McCrindle BW. Cardiovascular Consequences of Childhood Obesity. Can J Cardiol. 2015;31: 124–130. 10.1016/j.cjca.2014.08.017 [DOI] [PubMed] [Google Scholar]
  • 43.Chandrasekhar T, Suchitra MM, Pallavi M, Srinivasa Rao PVLN, Sachan A. Risk factors for cardiovascular disease in obese children. Indian Pediatr. 2017;54: 752–755. 10.1007/s13312-017-1169-0 [DOI] [PubMed] [Google Scholar]
  • 44.Elmaogullari S, Demirel F, Hatipoglu N. Risk factors that affect metabolic health status in obese children. J Pediatr Endocrinol Metab. 2017;30: 49–55. 10.1515/jpem-2016-0128 [DOI] [PubMed] [Google Scholar]
  • 45.Ognjanovic S, Jacobs DR, Steinberger J, Moran A, Sinaiko AR. Relation of chemokines to BMI and insulin resistance at ages 18–21. Int J Obes. 2013;37: 420–423. 10.1038/ijo.2012.61 [DOI] [PubMed] [Google Scholar]
  • 46.Kochumon S, Wilson A, Chandy B, Shenouda S, Tuomilehto J, Sindhu S, et al. Palmitate Activates CCL4 Expression in Human Monocytic Cells via TLR4/MyD88 Dependent Activation of NF-κB/MAPK/ PI3K Signaling Systems. Cell Physiol Biochem. 2018;46: 953–964. 10.1159/000488824 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Nayanatara Arun Kumar

16 Apr 2020

PONE-D-20-01403

Simultaneous evaluation of metabolomic and inflammatory biomarkers in children with different body mass index (BMI) and waist-to-height ratio (WHtR)

PLOS ONE

Dear  Aithors 

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review proco and Interprate the statistical analysis as suggested by the Reviewer. Likewise please do the changes in the 

==============================

We would appreciate receiving your revised manuscript  When you are ready to submit your revision, Kindly resubmit with al the quereiess recified 

log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Nayanatara Arun Kumar

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

1. Thank you for including your competing interests statement; "

I have read the journal's policy and the authors of this manuscript have the following competing interests: EPO is the Director of Fondo Nestlé para la Nutrición in the Fundación Mexicana para la Salud.

The other authors have indicated they have no financial relationships relevant to this article to disclose."

We note that one or more of the authors are employed by a commercial company: Fondo Nestlé para la Nutrición in the Fundación Mexicana para la Salud.

  1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Vadillo-Ortega and collaborators have studied changes in metabolic and inflammatory markers in obese children. Since these children show altered some of the metabolic markers but not those of inflammation, they conclude that the metabolic changes must precede the inflammatory ones.

It is difficult to follow the changes that occur, since the p values obtained in the ANOVAS or in the tests used are not indicated. These p-values must be included in order to be able to properly assess the changes that have occurred. In addition, although the differences obtained in the post-hoc tests are indicated, it is not clear what they refer to specifically. Perhaps it would be better to indicate the differences in the post-hoc tests, and between which groups, at the bottom of the tables.

Differences with reference 40 should be commented on more extensively, since the parameters evaluated were different. It would be interesting to evaluate leukocyte, lymphocyte, erythrocyte, platelet, CRP, and transaminase levels to see if the differences obtained in Marginean's and collaborators' study are also replicated in the children of the present study. I find it difficult, although this is a personal opinion, to think that only metabolic changes are the inducers of obesity in these children.

Minor points:

All numbers in all tables should always include a maximum of three significant digits. For example, in Table 1, the systolic pressure values include a figure of 104±10.5 and a figure of 108.2±12. The data should be more uniform, e.g. 104±11 and 108±12.

In table 1 the % is expressed and then the amount in parentheses; the amount should be indicated first and the percentage in parentheses (and the heading should be N (%)).

In Table 4, since the insulin values have been measured, they should be included.

Why were only 12 amino acids measured?

There is no difference between groups when comparing the different acyl-carnitines. It might be better to include this table as a supplementary table.

Reviewer #2: Manuscript describes an interesting cross sectional study that measured metabolic and inflammatory biomarkers in Mexican children with different levels of adiposity. Targeted metabolomics and appropriate statistical tools have been used for data analysis. Even with acknowledged limitations of relatively small sample size, lack of life-style and dietary data, study provides good information which would be very useful for future studies.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Aug 24;15(8):e0237917. doi: 10.1371/journal.pone.0237917.r002

Author response to Decision Letter 0


30 May 2020

Responses to Reviewer #1:

Corrections were made and highlighted in green, as they appear in the file named “Revised manuscript with track changes”.

1. p-values with statistical significance were included in tables. We modified all Tables to clarify their content. Old table 4 is now Supplementary Table 1 (S1). New Table 4 describes multivariate analysis.

2. Two paragraphs were added in Discussion addressing Marginean's study (Lines 299-304).

3. All numbers in tables were converted to include a maximum of three significant digits.

4. Insulin values were added in New Table 4.

5. Number of measured amino acids was limited by the pre-designed commercial kit. However, we selected this kit because all groups of amino acids were represented according to their metabolic fate.

6. Bivariate analysis that included acylcarnitines concentrations (old Figure 4) was included in Supplementary Table 1

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Nayanatara Arun Kumar

16 Jun 2020

PONE-D-20-01403R1

Simultaneous evaluation of metabolomic and inflammatory biomarkers in children with different body mass index (BMI) and waist-to-height ratio (WHtR)

PLOS ONE

Dear Dr. Felipe Vadillo-Ortega

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

   Dear authors 

           Based on the reviewers comment on this manuscript. considerin. Kindly submit the revised at the earlies

Please submit your revised manuscript by 30th June If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript 

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Nayanatara Arun Kumar

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Aug 24;15(8):e0237917. doi: 10.1371/journal.pone.0237917.r004

Author response to Decision Letter 1


17 Jul 2020

Mexico City, May 14,2020

Rebuttal letter

Responses to Reviewer #1:

Corrections were made and highlighted in green, as they appear in the file named “Revised manuscript with track changes”.

1. p-values with statistical significance were included in tables. We modified all Tables to clarify their content. Old table 4 is now Supplementary Table 1 (S1). New Table 4 describes multivariate analysis.

2. Two paragraphs were added in Discussion addressing Marginean's study (Lines 299-304).

3. All numbers in tables were converted to include a maximum of three significant digits.

4. Insulin values were added in New Table 4.

5. Number of measured amino acids was limited by the pre-designed commercial kit. However, we selected this kit because all groups of amino acids were represented according to their metabolic fate.

6. Bivariate analysis that included acylcarnitines concentrations (old Figure 4) was included in Supplementary Table 1

Additional changes:

Other corrections were made, they appear turquoise highlighted in the file named “Revised manuscript with track changes”.

1. Line 4: biomarkers instead of markers.

2. Line 8: corresponding author affiliation number.

3. Line 139: Gluc and TAG initials instead of Glucose and TG.

4. Line 149: initials of Insulin (Ins) was added.

5. Lines 151 and 152: initials of Gluc and Ins instead of the complete name.

6. Line 181, 192, 214, and 246: schoolchildren instead of school children.

7. Line 185, 196: initial definitions were included in the figure legend.

8. Line 189 -190, 250: NG initials instead of N.

9. Line 219- 227: all paragraph was modified.

10. Line 289 and 294: tyrosine and Val words were changed for phenylalanine, and ornithine such as valine (complete word).

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 2

Nayanatara Arun Kumar

6 Aug 2020

Simultaneous evaluation of metabolomic and inflammatory biomarkers in children with different body mass index (BMI) and waist-to-height ratio (WHtR)

PONE-D-20-01403R2

Dear Dr. Vadillo-Ortega,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Nayanatara Arun Kumar

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Dear authors

Very sorry for the delay in the decision from my side. The reviewers comments have been addressed and i congragulate all the auhtors . this paper can be accepted for the publication .

with best wishes

Dr. Nayana tara Arun KUmar

Associate Professor in Physiology

Kasturba Medical College, Mangalore

Reviewers' comments:

Acceptance letter

Nayanatara Arun Kumar

12 Aug 2020

PONE-D-20-01403R2

Simultaneous evaluation of metabolomic and inflammatory biomarkers in children with different body mass index (BMI) and waist-to-height ratio (WHtR)

Dear Dr. Vadillo-Ortega:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Nayanatara Arun Kumar

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Metabolic profile in schoolchildren classified by BMI or WHtR.

    Kruskal Wallis with Dunnett’s multiple comparison test were used to evaluate the parameters classified by BMI and, the U Mann Whitney test were used to evaluate parameters classified by WHtR. Significant differences (p < 0.05) between groups in both types of classification are shown with different letters. Gluc: Glucose, Ins: insulin, HOMA-IR: homeostasis model assessment insulin resistance, TG: triglycerides, TC: total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, C0: carnitine, C2: acetyl carnitine, C4: isobutyril carnitine, C6: hexanoyl carnitine, C8: octanoyl carnitine, C10: decanoyl carnitine, C12: dodecanoyl carnitine, C14: tetradecanoyl carnitine, C16: palmitoyl carnitine, C18: octadecanoylarnitine (stearoylcarnitine), C3: propionyl carnitine, C5: isovaleryl carnitine, Gly: glycine, Ala: alanine, Met: methyonine, Leu: leucine, Val: Valine, Phe: phenylalanine, Tyr: tyrosine, Arg: arginine, Cit: citrulline, Orn: ornitine, Pro: proline.

    (DOCX)

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES